Biotech Values

[DewDiligence]

IDIX CC notes (addendum):

--In 400 patients treated to date in all trials, NM283 has shown no sign of inducing resistance.

--Given that NM283 was tested in conjunction with Pegasys, the one SAE and two dropouts seen in 31 patients in the of 200mg arm of the treatment-naïve phase-2b trial (#msg-10883778) should be compared to the 10% rate of SAEs listed on the FDA Pegasys label. In other words, the rates of SAEs and dropouts in this trial arm were less than would be expected for patients treated with Pegasys alone.